Oppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)

In a report released today, Matthew Biegler from Oppenheimer maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a price target of $17.00. The company’s shares closed yesterday at $9.37.

According to TipRanks, Biegler is a 2-star analyst with an average return of 0.8% and a 34.32% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Oric Pharmaceuticals, Blueprint Medicines, and Alpine Immune Sciences.

Currently, the analyst consensus on Oric Pharmaceuticals is a Strong Buy with an average price target of $19.17, which is a 104.59% upside from current levels. In a report released yesterday, Citi also maintained a Buy rating on the stock with a $14.00 price target.

Based on Oric Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $28.33 million. In comparison, last year the company had a GAAP net loss of $20.85 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Oric Pharmaceuticals (ORIC) Company Description:

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely, ORIC-101 and ORIC-533.